| Autor: |
Shapiro JR; Bone Metabolism Research Laboratory, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Hopkins Bayview Research Campus, Baltimore, Maryland 21224, USA., Mcbride DJ Jr, Fedarko NS |
| Jazyk: |
angličtina |
| Zdroj: |
Connective tissue research [Connect Tissue Res] 1995; Vol. 31 (4), pp. 265-8. |
| DOI: |
10.3109/03008209509010820 |
| Abstrakt: |
Osteogenesis imperfecta (OI) is characterized by fragile bones, skeletal deformity, and growth retardation. This heritable disorder of connective tissue is the result of mutations affecting the COL1A1 and COL1A2 genes of type I collagen. Progress in OI research has been limited because of dependence on human fibroblast and osteoblast specimens and the absence of a naturally occurring animal model for this genetic disorder. Recent technology in molecular biology has led to the development of transgenic models of OI based on site directed mutagenesis of type I collagen genes. OIM is a naturally occurring model which incorporates both the phenotypic and biochemical defects of moderate to severe osteogenesis imperfecta. This powerful tool permits the development of models based on different type I collagen mutations. The collagen type I mutation in OIM is a C propeptide deletion which impairs the production of normal pro-alpha2(I). Tissues in OIM contain only [pro-alpha1(I)]3 homotrimer. Thus, although several animal models are now available for research in osteogenesis imperfecta few are viable or fully mimic human disease disorders. OIM duplicates the phenotype and biochemistry of human disease and has a normal life span. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
